A Phase II Study of CTLA Blockade by Ipilimumab Plus Androgen Suppression Therapy in Patients With an Incomplete Response to AST Alone for Metastatic Prostate Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 29 Mar 2017
At a glance
- Drugs Ipilimumab (Primary) ; Antiandrogens
- Indications Prostate cancer
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 23 Mar 2017 Planned End Date changed from 1 Apr 2018 to 18 Nov 2018.
- 23 Mar 2017 Planned primary completion date changed from 1 Jan 2017 to 22 Nov 2017.